Crescent Biopharma, a clinical-stage biotechnology company developing novel oncology therapies, recently initiated a global Phase 1/2 trial of its lead bispecific antibody CR-001 and plans to advance two antibody drug conjugates (ADCs) into clinical testing in 2026. The company’s strategy leverages combination therapies and a strategic partnership with Sichuan Kelun-Biotech to accelerate development. While Crescent holds a strong cash position with $171.6 million in cash and equivalents as of mid-2026, it faces ongoing net losses reflecting typical early-stage biotech capital intensity and high clinical risk. Success in clinical milestones and sustained financing will be critical to validate its differentiated bispecific approach versus existing immune checkpoint inhibitors.